Epizyme (EPZM) Getting Favorable News Coverage, Study Shows
News articles about Epizyme (NASDAQ:EPZM) have trended positive on Friday, according to Alpha One. The research group, a service of Accern, rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Alpha One ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Epizyme earned a coverage optimism score of 0.27 on Alpha One’s scale. Alpha One also assigned media coverage about the biopharmaceutical company an impact score of 30 out of 100, meaning that recent media coverage is unlikely to have an impact on the stock’s share price in the next few days.
These are some of the headlines that may have effected AlphaOne Sentiment Analysis’s scoring:
- Epizyme, Inc. breached its 50 day moving average in a Bearish Manner : EPZM-US : May 26, 2017 (finance.yahoo.com)
- Insider Selling: Epizyme Inc (EPZM) Insider Sells 15,000 Shares of Stock (americanbankingnews.com)
- LLC Has $812000 Position in Epizyme Inc (EPZM) (footballhebdo.com)
- First Week of July 21st Options Trading For Epizyme (EPZM) (stockoptionschannel.com)
- Epizyme Inc (EPZM) Downgraded by Zacks Investment Research to Hold (americanbankingnews.com)
A number of brokerages have recently commented on EPZM. Zacks Investment Research lowered Epizyme from a “buy” rating to a “hold” rating in a research note on Monday. HC Wainwright reissued a “buy” rating on shares of Epizyme in a research note on Friday, May 19th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $19.00 price objective (down from $26.00) on shares of Epizyme in a research note on Saturday, March 11th. Wedbush reaffirmed an “outperform” rating and issued a $24.00 price objective on shares of Epizyme in a research note on Thursday, May 18th. Finally, Cann reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Epizyme in a research note on Tuesday, April 25th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. Epizyme has an average rating of “Buy” and a consensus target price of $24.88.
Shares of Epizyme (NASDAQ:EPZM) traded down 3.41% during midday trading on Friday, reaching $15.60. The company’s stock had a trading volume of 362,803 shares. Epizyme has a 12-month low of $7.02 and a 12-month high of $18.50. The company’s market capitalization is $910.38 million. The company’s 50-day moving average price is $16.11 and its 200 day moving average price is $13.56.
Epizyme (NASDAQ:EPZM) last issued its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.07. Epizyme had a negative return on equity of 41.56% and a negative net margin of 1,205.01%. On average, equities research analysts forecast that Epizyme will post ($2.46) earnings per share for the current year.
In related news, insider Robert A. Copeland sold 5,000 shares of the stock in a transaction dated Tuesday, May 2nd. The stock was sold at an average price of $17.44, for a total transaction of $87,200.00. Following the completion of the sale, the insider now directly owns 36,538 shares in the company, valued at approximately $637,222.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew E. Singer sold 2,013 shares of the stock in a transaction dated Friday, March 31st. The shares were sold at an average price of $17.09, for a total value of $34,402.17. Following the sale, the chief financial officer now owns 36,175 shares of the company’s stock, valued at $618,230.75. The disclosure for this sale can be found here. Insiders have sold a total of 27,013 shares of company stock valued at $445,052 over the last 90 days. 25.40% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This article was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/05/26/epizyme-epzm-getting-favorable-news-coverage-study-shows.html.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Stock Ratings for Epizyme Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc and related stocks with our FREE daily email newsletter.